Pacer Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Pacer Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-59,189	Closed	-$1.56M	–	3369
2022 Q3	$1.56M	Buy	+59,189	New	+$2.17M	0.01%	449
2022 Q1	–	Sell	-25,979	Closed	-$1.32M	–	2599
2021 Q4	$1.32M	Buy	+25,979	New	+$1.35M	0.01%	1036
2021 Q3	–	Sell	-25,434	Closed	-$1.09M	–	1485
2021 Q2	$1.09M	Buy	25,434 +12,792	+101%	+$528K	0.02%	810
2021 Q1	$528K	Buy	12,642 +11,626	+1,144%	+$540K	0.01%	1033
2020 Q4	$47K	Buy	1,016 +132	+15%	+$6.17K	﹤0.01%	1422
2020 Q3	$38K	Buy	+884	New	+$38.7K	﹤0.01%	1316
2020 Q2	–	Sell	-1,669	Closed	-$87K	–	1004
2020 Q1	$87K	Sell	1,669 -4,040	-71%	-$203K	﹤0.01%	500
2019 Q4	$343K	Sell	5,709 -709	-11%	-$42.3K	0.02%	861
2019 Q3	$363K	Buy	6,418 +1,010	+19%	+$56.8K	0.01%	1050
2019 Q2	$301K	Buy	5,408 +857	+19%	+$44.7K	0.01%	1028
2019 Q1	$230K	Buy	+4,551	New	+$203K	0.01%	637
2018 Q4	–	Sell	-2,382	Closed	-$165K	–	1080
2018 Q3	$165K	Buy	2,382 +1,517	+175%	+$115K	0.01%	1048
2018 Q2	$65K	Buy	865 +503	+139%	+$31.6K	﹤0.01%	1095
2018 Q1	$19K	Sell	362 -1,082	-75%	-$62.9K	﹤0.01%	1018
2017 Q4	$77K	Buy	1,444 +947	+191%	+$52.7K	0.01%	981
2017 Q3	$30K	Buy	+497	New	+$30.1K	﹤0.01%	1140

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Pacer Advisors's EGRX Position: Q4 2022 in Review

Pacer Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2022, closing a stake of 59,189 shares — an estimated $1.56M sold.

Pacer Advisors first reported a position in EGRX in Q3 2017 and held it in 16 quarters. The position peaked at $1.56M in Q3 2022. 152 funds tracked by Wall St. Rank hold EGRX as of Q4 2022.

Pacer Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Pacer Advisors sold 59,189 Eagle Pharmaceuticals, Inc. shares in Q4 2022, an estimated $1.56M.
Pacer Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 16 quarters.
Pacer Advisors's Eagle Pharmaceuticals, Inc. position peaked at $1.56M in Q3 2022.
152 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2022.

Based on Pacer Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.